Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitri P Mikhailidis

Showing results (161-170 of 675) with videos related to

Pageof 68
Sort By:
Current Vascular Pharmacology|May 29, 2010
Management of statin-intolerant high-risk patientsKonstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Current Atherosclerosis Reports|October 22, 2008
Omega-3 fatty acids: how can they be used in secondary prevention?Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Expert Opinion on Pharmacotherapy|February 16, 2012
Stage of chronic kidney disease and severity of coronary heart disease manifestationVasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Current Vascular Pharmacology|November 25, 2011
Lipid lowering agents and the endothelium: an update after 4 yearsKonstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Current Pharmaceutical Design|September 11, 2020
Hypoglycaemia and Cardiovascular Disease Risk in Patients with DiabetesNiki Katsiki, Kalliopi Kotsa, Anca P Stoian, et al.
Current Medical Research and Opinion|May 16, 2014
The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 4, 2012
Hyperuricaemia: more than just a cause of gout?Niki Katsiki, Asterios Karagiannis, Vasilios G Athyros, et al.
Expert Opinion on Pharmacotherapy|June 4, 2015
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 20, 2023
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical OverviewOzge Telci Caklili, Mustafa Cesur, Dimitri P Mikhailidis, et al.
European Journal of Preventive Cardiology|August 14, 2021
Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overviewIoannis Parthymos, Michael S Kostapanos, Dimitri P Mikhailidis, et al.
Pageof 68

Showing results (161-170 of 675) with videos related to

Sort By:
Pageof 68
Current Vascular Pharmacology|May 29, 2010
Management of statin-intolerant high-risk patientsKonstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Current Atherosclerosis Reports|October 22, 2008
Omega-3 fatty acids: how can they be used in secondary prevention?Konstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Expert Opinion on Pharmacotherapy|February 16, 2012
Stage of chronic kidney disease and severity of coronary heart disease manifestationVasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Current Vascular Pharmacology|November 25, 2011
Lipid lowering agents and the endothelium: an update after 4 yearsKonstantinos Tziomalos, Vasilios G Athyros, Asterios Karagiannis, et al.
Current Pharmaceutical Design|September 11, 2020
Hypoglycaemia and Cardiovascular Disease Risk in Patients with DiabetesNiki Katsiki, Kalliopi Kotsa, Anca P Stoian, et al.
Current Medical Research and Opinion|May 16, 2014
The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps!Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Journal of Cardiovascular Medicine (Hagerstown, Md.)|October 4, 2012
Hyperuricaemia: more than just a cause of gout?Niki Katsiki, Asterios Karagiannis, Vasilios G Athyros, et al.
Expert Opinion on Pharmacotherapy|June 4, 2015
Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?Vasilios G Athyros, Niki Katsiki, Asterios Karagiannis, et al.
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 20, 2023
Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical OverviewOzge Telci Caklili, Mustafa Cesur, Dimitri P Mikhailidis, et al.
European Journal of Preventive Cardiology|August 14, 2021
Lipoprotein (a) as a treatment target for cardiovascular disease prevention and related therapeutic strategies: a critical overviewIoannis Parthymos, Michael S Kostapanos, Dimitri P Mikhailidis, et al.
Pageof 68